Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen has said it is to file nusinersen for spinal muscular atrophy (SMA) in infants after a phase 3 trial met primary endpoint. Biogen developed the drug in partnership with Ionis, and has ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

US biotech major Biogen (Nasdaq: BIIB) reported stronger-than-expected earnings for the first quarter of 2025, helped by ...

Biogen Inc. (Nasdaq ... 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA).

Biogen Q1 EPS hit $3.02 vs. $2.52 estimate; revenue rose 6% to $2.43 billion, beating the $2.23 billion consensus. Rare disease sales rose 33% to $563 million; Spinraza revenue climbed to $423.9 ...